此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

霍奇金淋巴瘤中的精子表观基因组 (SPELH)

2026年11月9日 更新者:Rennes University Hospital

癌症治疗诱导男性生殖系表观遗传不稳定的多参数检测与预防方法。

Cancer treatments can have long-term effects on fertility. In men, scientific studies suggest that the process of sperm formation (spermatogenesis) may be disrupted even years after recovery, with potential consequences not only for fertility but also for the health of offspring. The effects of chemotherapy on sperm quality, particularly on DNA packaging (chromatin) and the epigenome, remain poorly understood. Therefore, further in-depth studies are needed to determine whether a history of cancer and chemotherapy treatment may impact the health of children fathered by young male survivors.

We therefore propose to conduct a clinical study aimed at better understanding the mechanisms by which chemotherapies affect spermatogenesis. The results could provide answers by identifying the effects of these drugs on the fertility of young male cancer patients in the long term and the sperm epigenome indicative of the health of the progeny.

研究概览

地位

招聘中

详细说明

Advances in cancer treatments are raising new health questions for young survivors of the disease. Cancer itself and DNA-targeted treatments can have long-term effects on reproductive health. In men, spermatogenesis may remain impaired even years after recovery, with consequences for fertility and the health of offspring. It is important to note that sperm production can recover after cancer remission. However, men are advised to wait at least one year after the end of treatment before attempting natural conception, as gamete quality may influence reproductive capacity and offspring health. Yet, regardless of the mode of conception (natural or assisted reproduction), the question of whether a history of cancer and its treatment may affect the health of their offspring remains a fundamental issue that has not yet been clearly answered. In-depth studies are needed for this growing population of young cancer survivors who wish to have healthy children.

Where possible, the use of alkylating agents-known for their long-term systemic harmful effects-is being reduced, and less reprotoxic compounds, such as anthracyclines, are favored. Anthracyclines are widely used to treat various cancers prevalent in young men with a favorable survival prognosis and are classified as weakly reprotoxic (i.e., causing a temporary reduction in sperm count). However, they are suspected of having long-term effects on sperm chromatin and epigenome. The establishment of the sperm epigenome is a complex process resulting from multiple nuclear events during spermatogenesis, including chromatin remodeling and compaction that occur during spermiogenesis. These represent windows of opportunity for alteration by xenobiotics. Furthermore, genomic regions undergoing chromatin rearrangements may be more vulnerable to alterations; if these regions are located on key genes for embryonic development or fetal programming, they may predict adverse effects on offspring. In fact, emerging evidence suggests that sperm epigenetic marks could be used clinically to predict fertility and male-mediated developmental toxicity.

Here, we focus on young men with Hodgkin lymphoma (HL), one of the most commonly diagnosed malignant tumors at a young age, with a good prognosis and low risk of relapse, and for which treatment is well characterized using an anthracycline-containing protocol: doxorubicin. This pathology thus represents a large and relevant population of young cancer survivors who will consider parenthood after cancer. Due to interindividual variability, human studies aiming to determine the effects of chemotherapy must be able to compare samples before and after treatment in the same individual. Such published prospective longitudinal studies are rare and often include very few cases, as they require substantial resources, strong links between oncology and reproduction services, and the ability to follow patients over time, even after the end of oncological treatment. A (non-longitudinal) study of the long-term effects of HL treatments demonstrated persistent abnormalities in chromatin structure and DNA integrity. In the study proposed here, we will analyze epigenetic modifications in sperm from HL patients and their evolution after chemotherapy. We hypothesize that HL and its treatment induce persistent alterations up to 2 years after remission.

研究类型

介入性

注册 (估计的)

50

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Rennes、法国、35033

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 45年 (成人)

接受健康志愿者

是的

有资格学习的性别

男性

描述

Inclusion Criteria:

  • Men aged 18 to 45 years
  • Diagnosed with Hodgkin lymphoma
  • Treatment-naïve to any cytotoxic therapy
  • Whose treatment regimen consists of 4 to 6 cycles of ABVD or BrECADD
  • Beneficiaries of the French social security system
  • Not opposed to participating in research

Exclusion Criteria:

  • Patient receiving abdominal radiotherapy

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Epigenetic analysis in semen samples

30 men with hodgkin lymphoma will be followed during 24 months in order to search epigenetic modifications in male gametes

5 additional semen samples : before chemotherapy, at month 6, 12, 18 and 24 after chemotherapy. Each sperm sample will be stored in liquid nitrogen and sent to Institut National de la Recherche Scientifique (INRS), Quebec, Canada for epigenetic analysis.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Alterations in DNA methylation patterns in spermatozoa
大体时间:Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy

Sperm analysis : Methyl-C Capture Sequencing (MCC-seq)

Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy
Alterations of histone 3 H3k4me3 retention sites in spermatozoa
大体时间:Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy

Sperm analysis : chromatin immunoprecipitation followed by sequencing (ChIP-seq)

Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy

次要结果测量

结果测量
措施说明
大体时间
Spermogram exam
大体时间:Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy

Spermogram examination

Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy
Identification of known environmental factors impacting spermatogenesis
大体时间:Month 24 after chemotherapy

Patient questionnaire

Month 24 after chemotherapy

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Géraldine DELBES, PhD、Institut National de la Recherche Scientifique (INRS), Québec, Canada

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年11月9日

初级完成 (估计的)

2030年11月1日

研究完成 (估计的)

2030年11月1日

研究注册日期

首次提交

2025年12月3日

首先提交符合 QC 标准的

2026年2月26日

首次发布 (实际的)

2026年3月4日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • 35RC24_9822_SPELH

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅